Does the IL23R rs11209026 GG genotype lack the protective A allele effect against IBD?

The association between the IL23R gene and inflammatory bowel disease (IBD) is one of the most robust findings in gastrointestinal genetics. Research consistently identifies the rs11209026 polymorphism as a major determinant of disease susceptibility and protection.

Clinical and effectiveness evidence

The "A" allele (specifically the minor Gln variant at position 381) is a powerful protective factor against both Crohn’s disease (CD) and Ulcerative Colitis (UC).

• Risk reduction: Large-scale meta-analyses and genome-wide association studies (GWAS) involving thousands of patients show that carrying the A allele reduces the risk of developing Crohn’s disease by approximately 50–74%, with odds ratios typically reported between 0.26 and 0.50.
• Ulcerative Colitis: The protective effect is also present in UC, though often slightly less pronounced than in CD, with odds ratios ranging from 0.43 to 0.67.
• The GG Genotype: Because the A allele is the protective variant, individuals with the GG genotype (the common or "wild-type" homozygous state) do not benefit from this genetic risk reduction. The GG genotype represents the baseline risk population; while it does not inherently "cause" IBD, it lacks the potent molecular "brake" on inflammation provided by the A allele.

Mechanistic explanations

The protective effect of the A allele is driven by its "hypomorphic" nature, meaning it results in a receptor with reduced functional activity.

• Signaling disruption: The G-to-A substitution (p.Arg381Gln) occurs in the cytoplasmic tail of the IL-23 receptor. This change impairs the receptor's ability to recruit Janus kinase 2 (JAK2) and signal transducer and activator of transcription 3 (STAT3).
• Th17 pathway: IL-23 signaling is critical for the maintenance and activation of Th17 cells, which produce pro-inflammatory cytokines like IL-17 and IL-22. By attenuating this pathway, the A allele limits the chronic inflammatory cascade in the gut.
• Receptor stability: Evidence suggests the A variant may also reduce the stability or surface expression of the IL-23 receptor, further diminishing the immune system's responsiveness to pro-inflammatory IL-23 signals.

Clinical implications

While the A allele provides a significant protective advantage, the GG genotype is the standard state for the majority of the population (approximately 90-95% of Caucasians).

• Disease severity: Some studies indicate that among patients who already have Crohn’s disease, those with the GG genotype may experience a more aggressive disease course, including higher rates of surgical intervention, compared to those carrying the protective A allele.
• Population variance: It is important to note that the rs11209026 A allele is primarily found in populations of European descent and is extremely rare or absent in East Asian populations, where different IL23R variants may influence risk.

Bottom line

The claim is strongly supported by scientific evidence. The rs11209026 A allele provides significant protection against IBD by dampening pro-inflammatory IL-23 signaling. Consequently, individuals with the GG genotype lack this protective mechanism and remain at the standard baseline risk for developing chronic intestinal inflammation.